Certified Researchers

Salivary Gland Infection Market Summary

As per Market Research Future analysis, the Salivary Gland Infection Market Size was estimated at 0.8 USD Billion in 2024. The Salivary Gland Infection industry is projected to grow from USD 0.8471 Billion in 2025 to USD 1.501 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Salivary Gland Infection Market is poised for growth driven by technological advancements and increasing awareness of oral health.

Rising awareness of oral health is significantly influencing the Salivary Gland Infection Market, particularly in North America.
Advancements in diagnostic technologies, such as high-resolution ultrasonography, are enhancing detection capabilities and treatment outcomes.
The Asia-Pacific region is emerging as the fastest-growing market, driven by increasing healthcare investments and a rising geriatric population.
The increasing incidence of salivary gland infections and growing demand for preventive healthcare are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size	0.8 (USD Billion)
2035 Market Size	1.501 (USD Billion)
CAGR (2025 - 2035)	5.89%

Major Players

Johnson & Johnson (US), GlaxoSmithKline (GB), Merck & Co. (US), AbbVie (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Sanofi (FR), Pfizer (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Salivary Gland Infection Market Trends

The Salivary Gland Infection Market is currently experiencing notable developments, driven by a combination of factors including rising awareness of oral health and advancements in diagnostic technologies. As healthcare systems evolve, there is an increasing emphasis on early detection and effective treatment of salivary gland infections. This shift is likely to enhance patient outcomes and reduce the burden on healthcare resources. Furthermore, the growing prevalence of conditions that predispose individuals to salivary gland infections, such as autoimmune disorders, appears to be influencing market dynamics. The integration of innovative therapeutic approaches and the expansion of healthcare access may also contribute to the market's growth trajectory.

In addition, the Salivary Gland Infection Market is witnessing a surge in research and development activities aimed at improving treatment modalities. Pharmaceutical companies are exploring novel drug formulations and delivery systems, which could potentially enhance therapeutic efficacy. Moreover, the increasing collaboration between academic institutions and industry stakeholders suggests a commitment to addressing unmet medical needs in this area. As the market continues to evolve, stakeholders are expected to adapt strategies in line with emerging salivary gland infection market trends to capitalize on new growth opportunities.

Rising Awareness of Oral Health

There is a growing recognition of the importance of oral health in overall well-being. This trend is likely to drive demand for preventive measures and treatments related to salivary gland infections.

Advancements in Diagnostic Technologies

Innovations in diagnostic tools are enhancing the ability to detect salivary gland infections at earlier stages. This development may lead to improved patient management and treatment outcomes.

Research and Development Initiatives

Increased investment in research and development is fostering the creation of new therapeutic options for salivary gland infections. This trend indicates a proactive approach to addressing existing treatment gaps.

Salivary Gland Infection Market Drivers

Rising Geriatric Population

The rising geriatric population is a significant factor driving the Salivary Gland Infection Market. As the global population ages, the prevalence of chronic diseases and conditions that predispose individuals to salivary gland infections is expected to increase. Older adults often experience reduced salivary flow and other oral health issues, making them more susceptible to infections. This demographic shift necessitates the development of specialized treatment options and healthcare services tailored to the needs of the elderly. Consequently, the market is likely to see a surge in demand for products and services aimed at this vulnerable population, thereby enhancing growth prospects.

Growing Demand for Preventive Healthcare

The growing demand for preventive healthcare is a critical driver for the Salivary Gland Infection Market. As individuals become more health-conscious, there is an increasing emphasis on preventive measures to avoid infections. This trend is reflected in the rising sales of oral hygiene products and regular dental check-ups, which are essential in preventing salivary gland infections. Additionally, public health campaigns aimed at educating the population about the importance of oral health are likely to contribute to market growth. The focus on prevention not only enhances patient outcomes but also reduces the overall healthcare burden, thereby fostering a more robust market environment.

Increased Research and Development Activities

Increased research and development activities are propelling the Salivary Gland Infection Market forward. Ongoing studies aimed at understanding the pathophysiology of salivary gland infections and exploring novel therapeutic agents are crucial for market expansion. Pharmaceutical companies and research institutions are investing significantly in R&D to develop effective treatments and diagnostic tools. This focus on innovation is likely to lead to the introduction of new products that address unmet medical needs in the management of salivary gland infections. As a result, the market is expected to benefit from a continuous influx of advanced solutions, enhancing overall patient care.

Increasing Incidence of Salivary Gland Infections

The rising incidence of salivary gland infections is a notable driver for the Salivary Gland Infection Market. Factors such as poor oral hygiene, dehydration, and certain medical conditions contribute to this increase. Reports indicate that infections like sialadenitisare becoming more prevalent, particularly among older adults and individuals with compromised immune systems. This trend is likely to escalate the demand for effective treatment options and diagnostic tools within the market. As healthcare providers become more aware of these infections, the need for innovative therapies and preventive measures is expected to grow, thereby enhancing the overall market landscape.

Technological Advancements in Treatment Modalities

Technological advancements in treatment modalities are significantly influencing the Salivary Gland Infection Market. Innovations such as minimally invasive surgical techniques and the development of targeted therapies are transforming how these infections are managed. For instance, the introduction of endoscopic procedures has improved patient outcomes and reduced recovery times. Furthermore, the integration of telemedicine in consultations allows for timely diagnosis and treatment, which is crucial in managing salivary gland infections. As these technologies continue to evolve, they are likely to attract investment and research, thereby expanding the market and improving patient care.

Market Segment Insights

By Diagnosis: High-resolution ultrasonography (Largest) vs. Computed tomography (Fastest-Growing)

In the Salivary Gland Infection Market, the diagnosis segment encompasses various imaging techniques, each with distinct market shares. High-resolution ultrasonography currently leads the segment due to its non-invasive nature and ability to provide detailed images of salivary glands, making it the largest diagnostic modality used in clinical settings. Computed tomography (CT) follows with significant reliability for detecting complex salivary gland conditions, contributing to a diversified landscape where each modality serves unique diagnostic needs. The growth of the Salivary Gland Infection Market is primarily driven by advancements in imaging technology and increased awareness of salivary gland disorders. High-resolution ultrasonography continues to dominate due to its broad acceptance among healthcare professionals and patients. Conversely, computed tomography is witnessing the fastest growth, attributed to enhanced resolution capabilities and expanding applications in detecting malignancies and inflammatory conditions affecting the salivary glands.

High-resolution ultrasonography (Dominant) vs. Computed tomography (Emerging)

High-resolution ultrasonography stands out as the dominant diagnostic tool in the Salivary Gland Infection Market due to its ability to deliver real-time imaging without ionizing radiation, making it a safe option for patients. This method allows clinicians to visualize salivary structures accurately, facilitating timely diagnoses and treatment planning. In contrast, computed tomography, while traditionally used for its precision, is emerging rapidly as a favored option, particularly for complex cases that require detailed anatomical assessment and clarity in distinguishing between soft tissues. Its ability to provide comprehensive diagnostic information is making it increasingly preferred in clinical practice, driving its remarkable growth within this market segment.

By Treatment: Medication (Largest) vs. Surgery (Fastest-Growing)

In the Salivary Gland Infection Market, the treatment segment showcases a diverse range of approaches, with Medication leading the charge as the largest segment. This dominance is largely due to the accessibility and effectiveness of pharmacological therapies, which have consistently been preferred by both patients and healthcare providers. Following closely are Surgery, Aspiration, and Home Care, each holding their own share in the treatment paradigm. Aspiration and Home Care cater to specific cases and dual-function approaches, which contribute to their importance in comprehensive treatment plans for salivary gland infections. Growth trends in this segment are influenced by a multitude of factors, including advancements in medical technology and increasing awareness of salivary gland disorders. The urgency to treat infections promptly and effectively drives innovations in surgical techniques, making Surgery the fastest-growing treatment option. Additionally, the rising number of patients seeking non-invasive treatment options enhances the value of Aspirationand Home Care treatments, marking a significant shift toward more patient-centered care in the Salivary Gland Infection Market.

Medication (Dominant) vs. Home Care (Emerging)

Medication remains the dominant force within the Salivary Gland Infection Market treatment segment due to its proven efficiency in alleviating symptoms and preventing complications associated with infections. Antimicrobial therapies, anti-inflammatories, and pain relief medications lead the charge, providing both immediate and long-term benefits to patients. In contrast, Home Care is emerging as a significant alternative, particularly for patients seeking holistic and less invasive solutions. This trend is reflective of a greater focus on self-management and lifestyle modifications, which can complement traditional medical treatments. Home Careapproaches, such as warm compresses, hydration, and oral hygiene practices, are increasingly recognized for their role in recovery and maintaining gland function, marking their place in contemporary treatment strategies.

By End User: Hospitals & Clinics (Largest) vs. Medical Research Centers (Fastest-Growing)

The Salivary Gland Infection Market is primarily driven by the end-user segments of Hospitals & Clinics, Medical Research Centers, and Academic Institutes, with Hospitals & Clinics holding the largest share. These healthcare facilities are crucial in diagnosing and treating salivary gland infections due to the increasing prevalence of such conditions and the need for specialized care. Medical Research Centers, while currently smaller, are rapidly gaining traction owing to enhanced research activities and a focus on developing innovative treatments.

Hospitals & Clinics (Dominant) vs. Medical Research Centers (Emerging)

Hospitals & Clinics represent the dominant force in the Salivary Gland Infection Market, providing essential diagnostic and therapeutic services. Their extensive infrastructure, access to advanced medical technologies, and the ability to offer comprehensive care contribute to their leading position. In contrast, Medical Research Centers are emerging as key players, fueled by innovations in treatment methods and increasing investments in research activities. These centers focus on advancing medical knowledge and developing cutting-edge therapies, making them pivotal in addressing complex salivary gland infections and attracting funding for ongoing studies.

Get more detailed insights about Salivary Gland Infection Market

Request Free Sample

Regional Insights

North America : Healthcare Innovation Leader

North America is the largest market for salivary gland infections, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of salivary gland disorders, and significant investments in research and development. Regulatory support from agencies like the FDA further drives innovation and approval of new therapies, enhancing treatment options for patients. The United States is the leading country in this market, with major pharmaceutical companies such as Johnson & Johnson, Merck & Co., and AbbVie actively involved in developing new treatments. The competitive landscape is characterized by a focus on innovative therapies and biologics, with companies investing heavily in clinical trials to meet the growing demand for effective treatments. The presence of key players ensures a robust market environment, fostering continuous advancements in salivary gland infection management.

Europe : Emerging Market Dynamics

Europe is the second-largest market for salivary gland infections, accounting for approximately 30% of the global market share. The region is witnessing growth driven by increasing awareness of salivary gland disorders and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new therapies, which is essential for meeting the rising demand for effective treatments across member states. Leading countries in Europe include Germany, France, and the United Kingdom, where healthcare systems are increasingly prioritizing the management of salivary gland infections. The competitive landscape features key players like GlaxoSmithKline and AstraZeneca, who are actively engaged in research and development. The presence of these companies, along with a growing number of startups focusing on innovative solutions, is expected to enhance treatment options and improve patient outcomes in the region.

Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is an emerging powerhouse in the salivary gland infection market, holding approximately 20% of the global market share. The region is experiencing rapid growth due to increasing healthcare expenditure, rising awareness of salivary gland disorders, and a growing aging population. Countries like China and India are witnessing significant investments in healthcare infrastructure, which is expected to drive demand for effective treatment options in the coming years. China is the leading country in this region, with a burgeoning pharmaceutical industry that is increasingly focusing on innovative therapies for salivary gland infections. The competitive landscape is characterized by both local and international players, including Novartis and Sanofi, who are expanding their presence in the market. The growing number of clinical trials and collaborations between companies and research institutions is expected to enhance the development of new treatment modalities, further boosting market growth.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa represent a resource-rich frontier for the salivary gland infection market, holding approximately 5% of the global market share. The region faces challenges such as limited healthcare access and varying levels of awareness regarding salivary gland disorders. However, increasing investments in healthcare infrastructure and initiatives to improve disease awareness are expected to drive market growth in the coming years. Countries like South Africa and the United Arab Emirates are leading the way in addressing healthcare challenges and improving access to treatments. The competitive landscape is still developing, with a mix of local and international players. Companies are focusing on establishing partnerships and collaborations to enhance their market presence and improve treatment options for patients suffering from salivary gland infections, paving the way for future growth in this region.

Salivary Gland Infection Market Regional Image

Key Players and Competitive Insights

The Salivary Gland Infection Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of oral health and advancements in treatment modalities. Key players such as Johnson & Johnson (US), GlaxoSmithKline (GB), and Merck & Co. (US) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. Johnson & Johnson (US) has been particularly focused on enhancing its product portfolio through research and development, while GlaxoSmithKline (GB) emphasizes partnerships with healthcare providers to improve patient access to treatments. Merck & Co. (US) appears to be leveraging its strong pipeline of therapeutics to capture market share, indicating a collective shift towards a more integrated approach to addressing salivary gland infections.
The market structure is moderately fragmented, with several players vying for dominance. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is becoming increasingly vital in a post-pandemic world. The influence of major companies is significant, as they not only drive innovation but also set standards for quality and efficacy in treatment options. This competitive environment suggests that collaboration among these players may be essential for addressing the complexities of salivary gland infections effectively.
In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel therapeutic aimed at treating chronic salivary gland infections. This collaboration is expected to enhance AbbVie's research capabilities and expedite the development of innovative treatment options, thereby positioning the company as a leader in this niche market. The strategic importance of this partnership lies in its potential to leverage cutting-edge technology and expertise, which could significantly improve patient outcomes.
In September 2025, AstraZeneca (GB) launched a new clinical trial for a drug targeting salivary gland infections, aiming to assess its efficacy and safety in diverse populations. This initiative reflects AstraZeneca's commitment to expanding its therapeutic offerings and underscores the importance of clinical research in developing effective treatments. The trial's outcomes may not only influence AstraZeneca's market positioning but also contribute to the broader understanding of salivary gland infections.
In October 2025, Pfizer (US) unveiled a digital health platform designed to facilitate remote monitoring of patients with salivary gland infections. This innovative approach aims to enhance patient engagement and adherence to treatment regimens. The strategic significance of this platform lies in its potential to integrate technology into patient care, thereby improving health outcomes and operational efficiencies.
As of October 2025, current trends in the Salivary Gland Infection Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing patient care. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative treatment solutions, and reliable supply chains, reflecting a broader trend towards value-based healthcare.

Key Companies in the Salivary Gland Infection Market include

Future Outlook

Salivary Gland Infection Market Future Outlook

The Salivary Gland Infection Market is projected to grow at a 5.89% CAGR from 2025 to 2035, driven by increasing awareness, technological advancements, and rising healthcare expenditures.

New opportunities lie in:

Development of telemedicine platforms for remote diagnosis and treatment
Investment in advanced imaging technologies for early detection
Expansion of targeted antimicrobial therapies to reduce treatment resistance

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Salivary Gland Infection Market End User Outlook

Hospitals & Clinics
Medical Research Centers
Academic Institutes
Others

Salivary Gland Infection Market Diagnosis Outlook

Plain radiography
Sialography
High-resolution ultrasonography
Computed tomography (CT)
Magnetic Resonance Imaging (MRI)
Radionuclide scintigraphy
Others

Salivary Gland Infection Market Treatment Outlook

Medication
Surgery
Aspiration
Home care
Others

Report Scope

MARKET SIZE 2024	0.8(USD Billion)
MARKET SIZE 2025	0.8471(USD Billion)
MARKET SIZE 2035	1.501(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.89% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Johnson & Johnson (US), GlaxoSmithKline (GB), Merck & Co. (US), AbbVie (US), Bristol-Myers Squibb (US), AstraZeneca (GB), Novartis (CH), Sanofi (FR), Pfizer (US)
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in diagnostic technologies enhance early detection and treatment options in the Salivary Gland Infection Market.
Key Market Dynamics	Rising prevalence of salivary gland infections drives demand for advanced diagnostic and therapeutic solutions.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Salivary Gland Infection Companies

FAQs

What is the current valuation of the Salivary Gland Infection Market?

The Salivary Gland Infection Market was valued at 0.8 USD Billion in 2024.

What is the projected market size for the Salivary Gland Infection Market by 2035?

The market is projected to reach 1.501 USD Billion by 2035.

What is the expected CAGR for the Salivary Gland Infection Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.89%.

Which companies are considered key players in the Salivary Gland Infection Market?

Key players include Johnson & Johnson, GlaxoSmithKline, Merck & Co., AbbVie, and others.

What are the primary diagnostic methods used in the Salivary Gland Infection Market?

Primary diagnostic methods include Sialography, CT, and High-resolution ultrasonography, with valuations ranging from 0.1 to 0.35 USD Billion.

What treatment options are available for salivary gland infections?

Treatment options include medication, surgery, and aspiration, with medication alone valued between 0.32 and 0.62 USD Billion.

What are the main end-user segments in the Salivary Gland Infection Market?

Main end-user segments include Hospitals & Clinics, Medical Research Centers, and Academic Institutes, with Hospitals & Clinics valued at 0.32 to 0.64 USD Billion.

How does the market for salivary gland infections compare across different diagnostic methods?

The market for diagnostic methods shows varying valuations, with Sialography and CT leading at 0.15 to 0.3 USD Billion and 0.2 to 0.35 USD Billion, respectively.

What is the significance of the projected growth in the Salivary Gland Infection Market?

The projected growth indicates a rising demand for effective treatments and diagnostics, reflecting an increasing awareness and prevalence of salivary gland infections.

How are advancements in technology influencing the Salivary Gland Infection Market?

Advancements in imaging techniques and treatment methodologies are likely to enhance diagnostic accuracy and treatment efficacy, potentially driving market growth.

Author

Author

Vikita Thakur

Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Co-Author

Kinjoll Dey

Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of infectious disease surveillance databases, peer-reviewed otolaryngology and oral surgery journals, antimicrobial resistance tracking systems, and authoritative health organizations. Key sources included the US Centers for Disease Control and Prevention (CDC) National Notifiable Diseases Surveillance System, European Centre for Disease Prevention and Control (ECDC), World Health Organization (WHO) Global Oral Health Observatory and antimicrobial resistance surveillance network, National Institutes of Health (NIH) National Institute of Dental and Craniofacial Research (NIDCR), Infectious Diseases Society of America (IDSA) clinical practice guidelines, American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Foundation, American Dental Association (ADA) oral health surveillance data, National Center for Biotechnology Information (NCBI/PubMed) repository for sialadenitis and salivary gland disorder literature, Healthcare Cost and Utilization Project (HCUP) hospital discharge databases, EU Hospital Data Network, and national health ministry epidemiological reports from key markets. These sources were used to collect disease incidence statistics (sialadenitis, sialolithiasis, viral parotitis), antimicrobial prescription patterns, diagnostic imaging volume data, treatment outcome studies, and hospital admission trends related to salivary gland infections.

Primary Research

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. CEOs, VPs of clinical development, chiefs of regulatory affairs, and commercial directors from companies that provide antimicrobials, diagnostic imaging equipment, and salivary endoscopic devices were examples of supply-side sources. The demand-side sources included procurement leads from academic medical centers, ambulatory surgical centers, and tertiary care hospitals; board-certified otolaryngologists (ENT specialists); oral and maxillofacial surgeons; infectious disease specialists; head and neck radiologists; hospital pharmacy directors; and infection control specialists. Primary research confirmed pharmaceutical pipeline timelines for novel antibiotics and anti-inflammatory agents, validated market segmentation across diagnostic modalities (ultrasonography, CT, and sialography), and collected data on reimbursement dynamics for imaging and surgical procedures, clinical adoption patterns of minimally invasive sialendoscopy procedures, and the impact of antimicrobial stewardship on prescribing patterns.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through epidemiological modeling and revenue mapping across therapeutic and diagnostic segments. The methodology included:

Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in antimicrobial therapies (antibiotics, antivirals), anti-inflammatory drugs, and salivary gland diagnostic imaging systems

Product mapping across high-resolution ultrasonography devices, computed tomography systems, sialography equipment, contrast media, prescription medications (antibiotics, analgesics, sialagogues), and surgical intervention categories

Analysis of reported and modeled annual revenues specific to salivary gland infection treatment portfolios and diagnostic modalities

Coverage of manufacturers representing 70-75% of global market share in 2024

Extrapolation using bottom-up (disease incidence rates × treatment-seeking rate × average cost per treatment episode by country) and top-down (manufacturer revenue validation, hospital procurement data triangulation) approaches to derive segment-specific valuations for diagnosis (imaging modalities), treatment (medication, surgery, aspiration), and end-user settings (hospitals, research centers, academic institutes)